Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
On May 20, the U.S. Food and Drug Administration (FDA) approved Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent as a treatment for patients, aged 12 years and older, with eosinophilic esophagitis (EoE).
What was the data that prompted the FDA to make Dupixent the first and only medicine approved to treat EoE in the U.S.? And what is the sales potential of this indication for the pharma stock Sanofi? Let's dive into the clinical trial results and the EoE market to answer these questions.
EoE is an inflammatory disease that harms the esophagus and prevents it from working properly. The esophagus is the tube that connects the throat to the stomach. Patients with the condition experience an immune system reaction in which a type of white blood cell (eosinophil) accumulates in the esophagus. The symptoms of EoE include dysphagia (difficulty swallowing), central chest pain that doesn't respond to antacids, and food that is stuck in the esophagus after swallowing.
Source Fool.com
